Literature DB >> 16485072

Neurocognitive aspects of medication adherence in HIV-positive injecting drug users.

Drenna Waldrop-Valverde1, Raymond L Ownby, Frances L Wilkie, Alison Mack, Mahendra Kumar, Lisa Metsch.   

Abstract

Cognitive deficits are associated with nonadherence to HIV medications. HIV-positive injecting drug users (IDUs) are at particular risk for nonadherence and cognitive barriers to adherence specific to this population should therefore be identified. The present study assessed the relation of three domains of cognitive functioning, executive functions, memory, and psychomotor speed, to self-reported antiretroviral adherence in a sample of HIV-positive IDUs. Depression, use of alcohol, heroin, cocaine/crack, or marijuana in the last week were also included in the models. Logistic regression analyses showed that only psychomotor slowing was significantly associated with nonadherence. Executive functions, memory, depression, and active alcohol and substance use were unrelated to adherence. No other studies to date have exclusively linked psychomotor slowing to nonadherence in HIV infection. Psychomotor slowing among our study sample was severe and suggests that when evident, such slowing may be a valuable determinant for antiretroviral adherence among IDUs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485072     DOI: 10.1007/s10461-005-9062-6

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  26 in total

1.  Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention.

Authors:  R Douglas Bruce; Rebecca A Schleifer
Journal:  Int J Drug Policy       Date:  2008-01-15

Review 2.  The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review.

Authors:  Travis I Lovejoy; Julie A Suhr
Journal:  J Behav Med       Date:  2009-03-17

3.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

4.  Extrapyramidal motor signs in older adults with HIV disease: frequency, 1-year course, and associations with activities of daily living and quality of life.

Authors:  Savanna M Tierney; Steven Paul Woods; David Sheppard; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-12-10       Impact factor: 2.643

5.  Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS.

Authors:  Mark L Ettenhofer; Jessica Foley; Steven A Castellon; Charles H Hinkin
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

Review 6.  Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis.

Authors:  Olalekan A Uthman; Jessica F Magidson; Steven A Safren; Jean B Nachega
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

7.  Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients.

Authors:  Virender Kumar; William Encinosa
Journal:  Psychiatr Q       Date:  2009-04-22

8.  Randomized clinical trial of HIV treatment adherence counseling interventions for people living with HIV and limited health literacy.

Authors:  Seth C Kalichman; Chauncey Cherry; Moira O Kalichman; Christina Amaral; Denise White; Tamar Grebler; Lisa A Eaton; Dean Cruess; Mervi A Detorio; Angela M Caliendo; Raymond F Schinazi
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

9.  Intentional Medication Nonadherence Because of Interactive Toxicity Beliefs Among HIV-Positive Active Drug Users.

Authors:  Seth C Kalichman; Moira O Kalichman; Charsey Cherry; Ginger Hoyt; Christopher Washington; Tamar Grebler; Brandi Welles; Cindy Merely
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-15       Impact factor: 3.731

Review 10.  Cognitive neuropsychology of HIV-associated neurocognitive disorders.

Authors:  Steven Paul Woods; David J Moore; Erica Weber; Igor Grant
Journal:  Neuropsychol Rev       Date:  2009-05-22       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.